PTO/SB/08a (07-05)

Approved for use through 07/31/2006, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE entire Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

NT

Complete if Known

Application Number 10/533,654

Filing Date 05/04/2005

First Named Inventor William Brown

Art Unit Examiner Name

(Use as many sheets as necessary)

Attorney Docket Number | 100883-1P US

			U. S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2 (f known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
$\mathcal{S}\mathcal{A}$	Al	<sup>US-</sup> 3,940,386	02/24/1976	Szabo et al.	
•	A2	<sup>US-</sup> 5,574,159	11/12/1996	Chang et al.	
	<b>A3</b>	<sup>US-</sup> 5,681,830	10/28/1997	Chang et al.	
	A4	<sup>us-</sup> 5,807,858	09/15/1998	Chang et al.	
	A5	<sup>us-</sup> 5,854,249	12/29/1998	Chang et al.	
	A6	<sup>us-</sup> 6,130,222	10/10/2000	Roberts et al.	
	A7	<sup>US-</sup> 6,680,318	01/20/2004	Brown et al.	
	A8	<sup>US-</sup> 6,680,321	01/20/2004	Roberts et al.	
	A9	<sup>us-</sup> 6,696,447	02/24/2004	Brown et al.	
54	A10	<sup>US-</sup> 6,784,181	08/31/2004	Brown et al.	
9		US-			
		US-			· · · · · · · · · · · · · · · · · · ·
		US-			
		US-			
		US-			

	FOREIGN PATENT DOCUMENTS										
Examiner	Cite		Foreign Patent Document		Name of Patentee or	Pages, Columns, Lines,	ا ا				
Initials* No.'	Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)		MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear						
< M	B1	wo	86/04584	08/14/1986	Aktiebolaget Leo						
	B2	wo	91/07967	06/13/1991	Janssen						
	В3	wo	01/74805	10/11/2001	AstraZeneca AB	•					
	B4	wo	93/15062	08/05/1993	The Wellcome						
Su	B5	wo	97/23466	07/03/1997	Astra Pharma Inc.						

Examiner Signature Date Considered 4/3/2006

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 801.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08a (07-05) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known sostitute for form 1449A/PTO **Application Number** 10/533.654 Filing Date INFORMATION DISCLOSURE 05/04/2005 First Named Inventor STATEMENT BY APPLICANT William Brown Art Unit **Examiner Name** (Use as many sheets as necessary

Attorney Docket Number

100883-1P US

Examiner	Cite No.	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
Initials*	No.	Number-Kind Code <sup>2 (F known)</sup>	MM-DD-YYYY	Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	US-			
•		US-	***************************************		
		US-			···
		US-			
· · · · · · · · · · · · · · · · · · ·		US-			<del></del>
		US-			
····		US-			•
		US-	· · · · · · · · · · · · · · · · · · ·		
		US-	,		
		US-			
		US-	· · · · · · · · · · · · · · · · · · ·		
		US-		<u> </u>	
		US-			
		US-		<u> </u>	

Sheet

	FOREIGN PATENT DOCUMENTS										
Examiner	Cite		Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines,					
Initials*	No.1	Country C	ode <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> ( <i>if known</i> )	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T"				
SM	B6	wo	95/04051	02/09/1995	The Wellcome						
	B7	wo	98/28270	07/02/1998	Astra Aktiebolag						
<u> </u>	B8	wo	98/28275	07/02/1998	Astra Aktiebolag						
	B9	wo	99/33806	07/08/1999	Ortho-McNeil						
SIN	B10	EP	0289227	11/02/1988	Syntex						

Examiner Signature	$\overline{}$	T		Date	14/	5/5	
	يجيدك			Considere	·   · / ~	<u>3/0</u>	$\mathcal{O}\mathcal{C}$

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08a (07-05)
Approved for use through 07/31/2008, OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Sostitute for form 1448A/PTO

**Application Number** 

**Examiner Name** 

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

10/533,654 Filing Date 05/04/2005 First Named Inventor William Brown Art Unit

(Use as many sheets as necessary) Sheet

Attorney Docket Number | 100883-1P US

	U. S. PATENT DOCUMENTS									
Examiner initials*	Cite No.1	Document Number  Number-Kind Code <sup>2 (F known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear					
	<del></del>	US-			,					
		US-								
		US-		<del> </del>						
:		US-								
		US-								
<del></del>		US-								
		US-								
		US-								
		US-								
		US-								
		US-								
		US-								
		US-								
		US-								
		US-								
		US								
		US-								
		US-								

	FOREIGN PATENT DOCUMENTS											
Examiner		Cite		Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines,					
Initials	Initials* No.1		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>6</sup> (if known)		MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	Τ°				
4	1	B11	EP	0283310	09/21/1988	Sankyo Company						
		B12	EP	0166302	01/02/1986	Polindustria						
		B13	EP	0133323	02/20/1985	The Wellcome						
		B14	GB	2210366	06/07/1989	American Home		П				
12	Ŋ	B15	GB	2076403	12/02/1981	Selvi & C.S.p.A.		П				

Examiner Date Considered Signature EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant, 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08a (07-05)

Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
perwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

itute for form 1449A/PTO

## **INFORMATION DISCLOSURE** STATEMENT BY APPLICANT

Complete If Known **Application Number** 10/533.654 Filing Date 05/04/2005 First Named Inventor William Brown Art Unit **Examiner Name** 

(Use as many sheets as necessary) 9 Attorney Docket Number Sheet 100883-1P US

Examiner Initials*	Cite No.1	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where	
iniuais-	NO.	Number-Kind Code <sup>2 (F known)</sup>	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevar Figures Appear	
		US-				
•		US-				
		US-				
		US-	······································			
		US-				
		US-		†		
		US-				
		US-		-		
		US-	, , , , , , , , , , , , , , , , , , , ,			
		US-				
		US-			<u> </u>	
		US-				
		US-		<del></del>		
		US-				
		US-				
		US-	<del></del>			
·		US-			<u> </u>	
		US-				

	FOREIGN PATENT DOCUMENTS										
Examiner					Name of Patentee or	Pages, Columns, Lines,					
Initials*	No.'	Country C	Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	umber <sup>4</sup> Kind Code <sup>5</sup> ( <i>if known</i> )		Where Relevant Passages or Relevant Figures Appear	T°				
SM	B16	FR	2696744	04/15/1994	Laboratoires						
	B17	DE	2431178	01/16/1975	Cermol S.A.	***************************************					
	B18	DE	2900810	07/24/1980	Cassella AG	***************************************	П				
	B19	JР	7-138230	05/30/1995		*************************************	П				
5)M	B20	WO	97/23466	07/03/1997	Astra Aktiebolag	***************************************					

				<i>'</i>	
Examiner		Date	1	. /	
Signature	\	Considered	Y/ /2	7 ·/ \	
	V Ce	CONSIDER	(()		€00 (
*EYAMINED: Initial if soforoneo and	Money wheels are an all the state of the sta				<del></del>

R: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Substitute for form 1449A/PTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

PTO/SB/08a (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
INFORMATION DISCLOSURE
Filing Date

10/533,654

Filing Date

05/04/2005

First Named Inventor

William Brown

Art Unit
Examiner Name

Attorney Docket Number

100883-1P US

9

(Use as many sheets as necessary)

			U. S. PATENT C	OCUMENTS		
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant	
		Number-Kind Code <sup>2 (7 known)</sup>			Figures Appear	
		US-				
		US-				
	l —	US-	·			
		US-				
,		US-				
		US-				
<del></del> -		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
,		US-				
		US-				
		US-				
	ı	US-				

	FOREIGN PATENT DOCUMENTS										
Examiner	Cite	<u></u>	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines,					
Initials*	No.'	Country C	de <sup>3</sup> Number <sup>4</sup> Kind Code <sup>8</sup> (if known)		Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T°				
$\leq M$	B21	wo	92/04338	03/19/1992	The Up-John Co.						
	B22	EP	0624584	08/19/1998	Daiichi	***************************************					
	B23	wo	02/094794	11/28/2002	AstraZeneca AB	<del>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~</del>					
1	B24	wo	01/45637	06/28/2001	AstraZeneca AB	***************************************	П				
SM	B25	wo	01/46174	06/28/2001	AstraZeneca AB						

Examiner Signature

\*EXAMINER: Initial if reference considered, whether of not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 8 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08a (07-05) Approved for use through 07/31/2008. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known stitute for form 1449A/PTO **Application Number** 10/533.654 Filing Date INFORMATION DISCLOSURE 05/04/2005 First Named Inventor STATEMENT BY APPLICANT William Brown Art Unit **Examiner Name** (Use as many sheets as necessary) Attorney Docket Number 100883-1P US

Examiner	Cite No.1	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
Initials*	No.1	Number-Kind Code <sup>2 (# Incom)</sup>	MM-DD-YYYY	Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
•		US-			
	Í	US-	•		
		US-			
·		US-			
		US-		:	
		US-			······································
		US-			
		US-			
		US-			
		US-			<del> </del>
		US-			<del></del>
		US-			
		US-			1 100

	FOREIGN PATENT DOCUMENTS									
Examiner Initials*		Cite		Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines,			
Initials	s* 	No.'	Country Co	ode <sup>3</sup> 'Number <sup>4</sup> 'Kind Code <sup>5</sup> ( <i>if known</i> )	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	l ™		
9	1	B26	WO	2005/066148	07/21/2005	AstraZeneca AB				
		B27	wo	2004/041801	05/21/2004	AstraZeneca AB				
		B28	WO	2004/041800	05/21/2004	AstraZeneca AB	***************************************			
(QL	九	B29	WO	03/029215	04/10/2003	AstraZeneca AB	•••••••••••••••••••••••••••••••••••••••			
	•••••		****************	!**!**!**!****************************	***************************************		***************************************			

Examiner	Date 4//	$\overline{}$
Signature	Considered	
		1
SEVALABLE Description of the second		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08b (07-05)
Approved for use through 08/30/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OMB control number.

Ze Th	Substitute for f	orm 1449B/PTO				Complete if Known	
1					Application Number	10/533,654	
- 1	INFOR	MATION	DISCLO	SURE	Filing Date	05/04/2005	
STATEMENT BY APPLICANT					First Named Inventor	William Brown	
ł					Art Unit		
	(C	Jse as many sheet	s as necessary)		Examiner Name		
7	Sheet	7	of	9	Attorney Docket Number	100883-1P US	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*			T²
SM	C1	Bilsky et al., "SNC 80, A Selective, Nonpeptidic and Systemically Active Opioid Delta Agonist," J. Pharmacol. Experi. Ther. 273:359-366 (1995)	
	C2	Takemori et al., "Selective Natrexone-Drived Opioid Receptor Antagonists," Annu. Rev. Pharmacol. Toxicol. 32:239-269 (1992)	
	C3	Bilsky et al., "Characterization of Enantiomers of (+) BW373U86 and Related Compounds: Highly Selective Non-Peptidic Delta Opioid Agonists," Reg. Peptides 54:25-26 (1994)	
. C4		Calderon et al., "Probes for Narcotic Receptor Mediated Phenomena. 19. Synthesis of Opioid Receptor Agonist," J. Med. Chem. 37:2125-2128 (1994)	
	C5	Calderon et al., "Probes for Narcotic Receptor Mediated Phenomena. 23. Synthesis Opioid Receptor Ligands," J. Med. Chem. 40:695-704 (1997)	
C6		Chang et al., "A Novel, Potent and Selective Nonpeptidic Delta Opioid Receptor Agonist BW373U86," J. Pharmacol. Exper. Therap. 267:852-857 (1993)	
		Katrizky et al., "Benzotriazole-Mediated Arylalkylation and Heteroarylalkylation," Chem. Soc. Rev. 23:363-373 (1994)	
	C8	Kingsbury et al., "Synthesis of Structural Analogs of Leukotriene B and their Receptor Binding Activity," J. Med. Chem. 36:3308-3320 (1993)	
	С9	Lopez et al., "Exploring the Structure-Activity Relationships Opioid Receptor Nonpeptide Agonist Ligand," J. Med. Chem. 42:5359-5368 (1999)	
9M	C10	Plobeck et al., "New Diarylmethylpiperazines as Potent and Selective Nonpeptidic Opioid Receptor Agonists with Increased In Vitro Metabolic Stability," J. Med. Chem. 43:3878-3894 (2000)	***********

Examiner Date 24/				
	Examiner	Date	4/5/	1001
Signature Considered 5/0000		Considered		+000

<sup>\*</sup>EXAMINER: elnitial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to expend the terms and or surgestions for reducing this burden, should be sent to the Check Information Officer, ILS. Retent on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTC/SB/08b (07-05)
Approved for use through 08/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	orm 1449B/PTO	•			Complete If Known	
3A CHANGE				Application Number	10/533,654	
INFOR	MATION DI	ISCLO	SURE	Filing Date	05/04/2005	
STATE	EMENT BY	APPLI	CANT	First Named Inventor	William Brown	
				Art Unit		
(C	Use as many sheets as	s necessary)		Examiner Name		
Sheet	8	of	9	Attorney Docket Number	100883-1P US	

	NON PATENT LITERATURE DOCUMENTS						
Examiner [nitials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²				
- Jul	CII	Suggs et al., "Facile Synthesis fo 8-Substituted Quinolines," J. Org. Chem., 45:1514-1515 (1980)					
	C12	Zhang et al., "Probes for Narcotic Receptor Mediated Phenomena. 26. Synthesis Opioid Receptor Ligands," J. Med. Chem. 42:5455-5463 (1999)					
	C13	English Abstract for Reference B16 on PTO/SB/08A, Page 4					
•	C14	English Abstract for Reference B17 on PTO/SB/08A, Page 4					
	C15	English Abstract for Reference B18 on PTO/SB/08A, Page 4					
	C16	English Abstract for Reference B19 on PTO/SB/08A, Page 4					
	C17	Burkey et al., "The Efficacy of Delta-Opioid Receptor-Selective Drugs," Medline Abstract for Life Sci. 62:1531-1536 (1998)					
	C18	Nagase et al., "The Pharmacological Profile of Delta Opioid Receptor Ligands, (+) and (-) TAN-67 on Pain Modulation," Medline Abstract for Life Sci. 68:2227-2231 (2001)					
	C19	Green, "Protective Groups in Organic Synthesis," pgs. 267-268 and 331 (1981)					
$\mathcal{A}$	C20	Abstract for HU 217619. A corresponding English language PCT application is cited as Reference B1 listed on PTO/SB/08A, Page 1					

		I
Examiner Signature	Date Considered	1006
	<u> </u>	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTC/SB/08b (07-05)
Approved for use through 06/30/2008, OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

se Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449B/PTO Complete If Known Application Number 10/533,654 Filing Date INFORMATION DISCLOSURE 05/04/2005 First Named Inventor STATEMENT BY APPLICANT William Brown Art Unit (Use as many sheets as necessary) Examiner Name Attorney Docket Number | 100883-1P US Sheet 9

	NON PATENT LITERATURE DOCUMENTS							
Examiner Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.						
SW	Abstract for HU 215847. A corresponding English language PCT application is cited as reference B2 on PTO/SB/08A, Page 1							
	C22	Nortey et al., "Piperazinyl Benzamidines: Synthesis and Affinity for the Delta Opioid Receptor," Bioorganic & Medicinal Chemistry Letters, Vol. 11, pgs. 1741-1743 (2001)						
$\Delta \Lambda$	C23	Snyder et al., "Historical Review: Opioid Receptors," Trends in Pharmacological Sciences, Vol. 24, pgs. 198-205 (2003)						
	•••••							
		.4						
	************							
	,							
	······································							
h								

Examiner Signature	71	Date Considered	4///	1006
Signature	0/20	Considered	1010	<u> </u>

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.